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Abstract 
The Steroid receptor RNA activator (SRA) gene has been implicated in estrogen receptor signaling pathwy. First 
identified as a RNA coregulator, SRA had been shown to increase steroid receptor activity. SRA RNA expr ssion is 
altered during breast tumorigenesis and its molecular role in underscoring these events has been suggeted. The 
subsequent identification of molecules capable of binding SRA, including RNA helicase p68, SRA stem-loop 
interacting RNA binding protein (SLIRP), and steroidogenic factor 1 (SF1) indicates SRA function is not exclusively 
limited to modulate steroid receptor activity. A recent genome-wide expression analysis by depleting SRA in cancer 
cells has further expanded our understanding of a bro der biological role played by SRA. In addition, several RNA 
isoforms have been found to encode an endogenous protein (SRAP), which is well conserved among Chordata. 
Interestingly, SRAP also modulates steroid receptor activity and functions as a co-regulator in estrogen receptor 
signaling. The recent observation that a higher expession of SRAP protein is associated with poorer survival in breast 
cancer patients treated with tamoxifen, highlights t e potential relevance of this protein in cancer. Together, the SRA1 
gene encodes both functional RNA and protein (SRAP) products, making it a unique member amongst the growing 
population of steroid receptor co-regulators. 
 
1. Introduction 
It is now quite apparent that the end results of Estrogen 
Receptor (ER) mediated signaling is not simply limited 
to ER status and/or the presence of its naturally 
occurring ligand estridiol. In addition to the two known 
estrogen receptors, ERα and ERβ, ERs-mediated gene 
transcription also requires transcription co-regulators, 
which form complexes with estrogen receptors through 
protein-protein interactions followed by dynamic 
recruitment to specific gene promoters. Based on the 
outcomes of their regulations, co-regulators are 
categorized as either co-activators or co-repressors if 
they either promote or prevent gene transcription 
respectively. These complexes regulate the assembly 
and activity of the transcription initiation complex 
through chromatin remodeling (McKenna et al., 1999; 
Jenuwein and Allis, 2001).  
Since the characterization of the first co-regulator, he 
steroid receptor co-activator 1 (SRC-1), this list of 
factors has grown significantly to now include over 300 
co-regulators (Lonard and O'Malley, 2007). One 
particularly interesting member within this family was 
identified by Lanz et al. in 1999, as it was found not to 
act as a protein molecule but as a functional RNA. This 
nuclear co-regulator was therefore named Steroid 
receptor RNA activator (SRA) (Lanz et al., 1999). 
2. Steroid Receptor RNA Activator 
(SRA) 
2.1 Discovery of SRA, an RNA Co-activator 
In order to identify new potential co-regulators 
interacting with AF-1 domain of the progesterone 
receptor (PR), Lanz screened a human B-lymphocyte 
library using AF-1 domain as bait in a  
yeast-two-hybrid assay (Lanz et al., 1999). They 
identified a new clone, they called SRA, for steroid 
receptor RNA activator. This cDNA was unable to 
encode a protein, but was required for the growth of t e 
yeast colony. Further experiment confirmed that the
potential co-activation role of SRA on PR was 
mediated through a RNA transcript rather than any 
protein product. 
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2.2 Core sequence of SRA and predicted functional 
region 
In the incipient SRA study, a core sequence spanning 
SRA exon 2 to exon 5 was found to be necessary and 
sufficient for co-activation function of SRA RNA 
(Figure 1, Lanz et al., 1999). Several predicted 
secondary RNA structural motifs are distributed 
throughout this core sequence, and are believed to form 
the functional structures that impart SRA activities. 
Site-directed mutagenesis experiment revealed six 
secondary structural motifs (STR1, 7, 9, 10, 11, 12) that 
independently participate in PR co-activation by SRA 
(Lanz et al., 2002). It was found that silent mutations in 
both SRT1 and STR7 of SRA could decrease by more 
than 80% co-activation SRA's function (Lanz et al., 
1999). 
2.3 Effect of SRA RNA on ERα and ERβ signaling 
Several research groups have now confirmed that SRA  
is able to increase estradiol induced gene transcription 
by both full length ERs subtypes (Watanabe et al., 
2001; Deblois and Giguère, 2003; Coleman et al., 
2004; Klinge et al., 2004). SRA RNA has been shown 
to co-activate the action of the AF-2 domain of both 
ERα and ERβ in a ligand-dependent manner on some, 
but not all estrogen receptor element (ERE) as measur  
through luciferase reporters assay (Deblois and 
Giguère, 2003; Coleman et al., 2004).  
Interestingly, SRA can also enhance AF-1 domain of 
ERα but not ERβ in a ligand-independent manner 
(Coleman et al., 2004; Deblois and Giguère, 2003). 
Overall, data suggest that the action of the two estrogen 
receptors are differentially regulated by SRA and SRA 
regulation of a given receptor is also specific of a given 
ERE sequence (Leygue, 2007). 
2.4 Emerging mechanisms of SRA RNA action 
Several studies have been published discussing the 




Figure 1. SRA1 genomic structure and core sequence. A) SRA sequences were originally described, differing in their 5' and 3' 
extremities, but sharing a central core sequence depicted in light blue (Lanz et al., 1999). One sequence has been registered with the 
NCBI nucleotide database (AF092038). Alignment with chromosome 5q31.3 genomic sequence is provided. Introns and exons are 
represented by black lines and blue boxes, respectively. B) Schematic profile of the predicted secondary structure of human core SRA 
RNA. The secondary structure profile of SRA core sequence has been modeled using Mfold software (Zuker, 2003). Detailed structure of 
STR1, 10, 7 (Lanz et al., 2002) is provided. C) By doing site-directed mutagenesis experiment, six secondary structural motifs (STR1, 9, 
10, 7, 11, 12) have been identified to participate in co-activation respectively. Especially, silent mutations in both SRT1 and STR7 of SRA 
could nullify above 80% SRA co-activation function (Lanz et al., 2002). 
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Firstly, SRA's coactivation function is activated by two 
pseudouridylases, Pus1p and Pus3p, which have also 
been characterized as co-activators (Zhao et al., 2007). 
This modification alters the secondary structure and 
rigidity of the target SRA RNA molecules to promote 
proper folding, resulting in synergized co-activation 
function (Charette and Gray, 2000). The other positive 
regulators include the receptor co-activator 1 (SRC-1) 
(Lanz et al., 1999) and the RNA helicases P68/72 
(Watanabe et al., 2001). SRC-1 belongs to p160 family 
co-activators (SRC1, SRC2/TIF2 and SRC3/AIB1), 
which can recruit other co-regulators to steroid 
receptors as well as promote a functional synergy 
between AF-1 and AF-2 domains (Louet and O'Malley, 
2007; McKenna et al., 1999; Smith and O'Malley, 
2004). Using co-immunoprecipitation from an 
expression system consisting of Xenopus oocytes 
programmed with in vitro generated RNA, SRA was 
found to associate with SRC-1 (Lanz et al., 1999). The
p72/p68 proteins are DEAD-box RNA binding 
helicases that can physically interact with p160 family 
proteins and with ERα. AF-1 region (Caretti et al., 
2007). The p72/p68 is able to bind to SRA through a 
well conserved motif in the DEAD box and synergizes 
with SRA and SRC2/TIF2 to co-activate ERα activity 
in the presence of estradiol (Caretti et al., 2006). 
On the other side, SRA may also serve as a platform t  
recruit some negative regulators consisting of the 
SMRT/HDAC1 associated repressor protein (SHARP) 
(Shi et al., 2001) and the SRA stem-loop interacting 
RNA binding protein (SLIRP) (Hatchell et al., 2006). 
SHARP was found to physically interact with 
corepressors through its repression domain (RD) 
whereas it interacts with SRA through a RNA 
recognition motif (RRM) (Shi et al., 2001). Similarly, 
SLIRP specifically binds to SRA STR-7 and attenuates 
SRA-mediated transactivation of endogenous ER 
(Hatchell et al., 2006). 
The emerging model of SRA action on ERα signaling 
had been summarized: Pus1p pseudouridylates specific 
SRA RNA uridine residues, leading to an optimum 
configuration of this RNA.  
The resulting active form of SRA, could stabilize 
complexes with p68 and SRC-1. In this case, 
transcription of target genes with suitable ERE will 
occur. In contrast, interaction with the negative 
regulators SLIRP and SHARP with SRA RNA may 
result in the inhibition of ER-mediated transcription. It 
has been proposed that they might act by sequestrating 
SRA by destabilizing the complex SRA/SRC-1 or by 
recruiting the nuclear receptor corepressor N-CoR at 
the promoter region of silenced genes (Leygue, 2007).  
2.5 A broader biological role played by SRA 
It has been previously established that SRA action is 
not exclusively limited to increasing steroid  
receptor activity. Indeed it was also confirmed that 
SRA enhance the activity of other nuclear receptor 
(NRs), such as retinoic acid receptors, thyroid receptors 
(Zhao et al., 2004; Xu and Koenig, 2004) as well as the 
activity of MyoD, a transcription factor involved in 
skeletal myogenesis (Caretti et al., 2006; Caretti et al., 
2007); SF-1 and DAX-1, orphan NRs that plays critical 
roles in the regulation of sex determination, adrenal 
development steroidogenesis (Xu et al., 2009). 
Recently, Foulds et al. investigated the global changes 
in gene expression by microarray analyses in two 
human cancer cell lines when SRA RNA was depleted 
by small interfering RNAs (Foulds et al., 2010). 
Unexpectedly, only a small subset of direct estrogen 
receptor-target genes was affected in estradiol-treated 
MCF-7 cells. However, they found many target genes 
involved in diverse biological roles such as glucose 
uptake, cellular signaling, T3 hormone generation were 
altered upon SRA depletion. This suggests SRA has a 
much broader upstream biological impact within the 
cell than simply a corgualtor of ER-signaling.  
2.6 SRA RNA expression and relevance to breast 
cancer 
Different SRA transcripts, detected by Northern blot, 
have been observed in normal human tissues (Lanz et 
al., 1999). SRA seems highly expressed in liver, 
skeletal muscle, adrenal gland and the pituitary gland, 
whereas intermediate expression levels are seen in the 
placenta, lung, kidney and pancreas. Interestingly, brain 
and other typical steroid-responsive tissues such as 
prostate, breast, uterus and ovary contained low levels 
of SRA RNA (Lanz et al., 1999). However, SRA RNA 
expression, assessed by RT-PCR amplification, is 
increased during breast and ovarian tumorigenesis 
(Lanz et al., 2003; Leygue et al., 1999; Hussein-Fikret 
and Fuller, 2005). Interestingly, SRA over-expression 
might characterize particular subtypes of lesions among 
different tumors. Indeed, serous ovarian tumors 
expressed higher levels of SRA than granulosa cell 
tumors (Hussein-Fikret and Fuller, 2005).  
The involvement of SRA in ER action suggests 
possible SRA role in breast tumor pathology. Indeed, 
ER-α-positive/PR-negative breast tumors expressed 
more SRA than ER-α-positive/PR-positive breast 
tumors (Leygue et al., 1999), whereas Tamoxifen-
sensitive and resistant breast tumors express similar 
levels (Murphy et al., 2002). However, generation of 
transgenic mice has however demonstrated that over-
expression of the core SRA sequence in the mammary 
gland only led to pre-neoplastic lesions but was not 
sufficient per se to induce tumorigenesis (Lanz et al., 
2003). Notably, SRA gene depleted MDA-MB-231 
cells are less invasive than control cells, indicating his 
gene might be also critical for invasion (Foulds et al., 
2010). 
3. Coding SRA and SRAP  
3.1 Discovery of SRAP 
Kawashima et al. reported in 2003 the cloning of a new 
rat SRA cDNA mostly identical to the core SRA 
sequence from exon 2 to exon 5. This cDNA was,  
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however translatable in vitro encoding a putative 16 kD 
protein starting at the third methionine codon of the rat 
SRA cDNA sequence (Kawashima et al., 2003). It 
should be stressed that the existence of a corresponding 
endogenous 16 kD SRAP has never been proved.  
In the nucleotide database of the National Center for 
Biotechnology Information (NCBI), most human SRA 
sequences contain an intact core sequence (exon-2 t 
exon-5) but differ in their 5'-extremity. Interestingly, 
some variants having 5' end extention contain two start 
codons with a large open reading frame potentially 
encoding a 236/237 amino acid peptide. These cDNAs, 
as opposed to the original SRA, were translatable in 
vitro, as well as in vivo, leading to the production of a 
protein localized both in the cytoplasm and the nucle s 
(Emberley et al., 2003). In addition, sequence of SRAP 
is highly conserved among chordate and the presence 
of endogenous SRAP had been found in the testes, 
uterus, ovary and prostate, as well as mammary gland, 
lung and heart (Chooniedass-Kothari et al., 2004). 
Altogether, accumulated data has demonstrated that 
SRA1 gene products consist of two characteristic 
entities: a functional RNA, which through its core 
sequence, can co-activate transcription factor and  
protein whose function remains yet to be fully 
understood. 
3.2 Function of SRAP 
Chooniedass-Kothari et al. reported the existence of 
putative endogenous human SRA protein in breast 
cancer cells (Chooniedass-Kothari et al., 2006). A 
decreased response to ERα activity was observed in 
MCF-7 cells stably transfected with SRAP suggested 
that this protein might repress estrogen receptor 
activities (Chooniedass-Kothari et al., 2006). This 
result contrasts with Kawashima's results, who found 
that the transient transfection of full length rat SRA 
coding sequence and led to an activation of the 
response to androgen (Kurisu et al., 2006). It should be 
pointed out that, both coding sequence of SRA used by 
these two groups also contains the functional core 
sequence of SRA RNA proven to co-activate ERα. 
Therefore, it is difficult to draw any conclusions 
regarding the individual function of SRAP on estrogen 
receptor activities when functional SRA RNA and 
SRAP protein are co-expressed.  
In order to understand the functional role of SRAP 
independently of SRA RNA, two different groups have 
investigated physical protein properties by tandem 
mass spectrometric analysis of SRAP co-
immunoprecipitation samples (Jung et al., 2005; 
Chooniedass-Kothari et al., 2010). Interestingly, both 
groups showed that SRAP is able to interact with 
transcriptional regulators. In Chooniedass-Kothari's 
unpublished results using mass spectrometry, MBD3 
(methyl-CpG binding domain protein 3, a member of 
the nucleosome remodeling and histone deacetylase 
complex, Nurd), BAF 57 (a core subunit of SWI/SNF 
chromatin remodeling complex) and YB-1 (Y-box 
bindng protein, a general transcription factor) have 
been found to interact with SRAP (Jung et al., 2005; 
Chooniedass-Kothari et al., 2010). By using a similar 
approach, Jung et al. also found that the transcription 
regulators, such as, BAF 170 (BRG1 associated factor 
170, also belonging to SWI/SNF chromatin remodeling 
complex) and YB-1 are associated with SRAP (Jung et 
al., 2005). It is necessary to point out that different cell 
line models and antibodies were used in these two 
groups. Jung et al. used Hela cell lines and 743 
antibody (commercial available rabbit polyclonal 
antibody) whereas Chooniedass-Kothari used MCF7 
cells stably over-expressed V5 tagged SRAP and V5 
antibody.  
Interestingly, nobody has confirmed any protein-
protein interaction between SRAP and those potential 
partners by co-immunoprecipitation experiments. 
The observation that SRAP forms complexes with 
transcription factors by mass spectrometric analysis led 
us to investigate its direct association with transcription 
factors.  
By using recombinant SRAP and protein arrays, 
Chooniedass-Kothari found that SRAP interact with 
different transcription factors including ERα and ERβ 
with different binding affinities (Chooniedass-Kothari 
et al., 2010). To further validate the interaction between 
ER and SRAP, we performed GST pull down assay and 
a direct interaction between GST-SRAP and both full 
length radio-labeled estrogen receptor α and β was 
observed (Chooniedass-Kothari et al., 2010). 
Interestingly, Kawashima showed that SRAP is also 
able to directly interact with the AF-2 domain of AR in 
vitro by doing GST pull down assay (Kawashima et al., 
2003). 
3.3 Alternative RNA splicing of SRA gene in breast 
cancer 
The balance between co-activators and co-repressors 
may ultimately controls estrogen action in a given 
tissue (Lonard and O'Malley, 2006). A direct 
participation of this balance during breast 
tumorigenesis and cancer progression is now suspected, 
and a search for possible means to control it has started 
worldwide (Perissi and Rosenfeld, 2005; Hall and 
McDonnell, 2005). Alternative splicing of SRA gene 
might control the balance between the coding and non-
coding SRA, and ultimately might function as the 
potential mechanism to regulate the balance between 
co-activators and co-repressors.  
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Figure 2: Coding and non-coding SRA transcripts in human breast cancer cells. SRA1 gene, located on chromosome 5q31.3, 
consists of 5 exons (boxes) and 4 introns (plain lines). The originally described SRA sequence (AF092038) contains a core sequence 
(light blue), necessary and sufficient for SRA RNAs to act as co-activators (Lanz et al., 1999). Three coding isoforms have now been 
identified (SRA1, SRA2, SRA3), which mainly differ from AF092038 by an extended 5'-extremity containing AUG initiating codons 
(vertical white bar in exon 1). The stop codon of the resulting open reading frame is depicted by a black vertical bar in exon5. Black stars 
in exon 2 and 3 correspond to a point mutation (position 98 of the core: U to C) and a point mutation followed by a full codon (position 
271 of the core: G to CGAC), respectively. Three non-coding SRA isoforms containing a differentially-spliced intron-1 have been 
characterized: FI, full intron-1 retention; PI, partial intron-1 retention; AD, alternative 5' donor and partial intron retention. Thick straight 
line, 60 bp of intron 1 retained in PI; triangulated lines represent splicing events (Modified from Cooper et al. 2009). 
 
Both non-coding and coding SRA transcripts co-exist 
in breast cells (Figure 2, Hube et al., 2006). Using a 
previously validated triple-primer PCR (TP-PCR) assay 
(Leygue et al., 1996), which allows co-amplification 
and relative quantification of two transcripts sharing a 
common region but differing in another, we found that 
breast cancer cell lines co-expressed normally spliced 
coding SRA RNA as well as SRA RNA containing 
intron-1 (Hube et al., 2006). Interestingly, breast cancer 
cell lines differ in their relative levels of coding/non-
coding SRA transcripts. In particular, the three most 
invasive cell lines (MDA-MB-231, 468, and BT-20) 
expressed the highest, whereas the "closest to normal" 
MCF-10A1 breast cells expressed the lowest relative 
levels of SRA intron-1 RNA. This suggests that a 
balance changed toward the production of non-coding 
SRA1 RNA in breast cells might be associated with 
growth and/or invasion properties (Hube et al., 2006). 
Alternative splicing events result from the relative local 
concentration of RNA binding proteins within the 
microenvironnement surrounding the nascent pre-
mRNA (Mercatante et al., 2001). We were recently 
able to artificially alter the balance between coding and 
non-coding SRA1 RNAs in T5 breast cancer cells using 
a previously described splicing-switching 
oligonucleotide strategy (Mercatante et al., 2001; 
Mercatante and Kole, 2002). This approach resulted in 
an increase in the production of intron retained 
transcripts, decrease in the expression of SRAP, 
resulting in an observed significant increase in the
expression of the urokinase plasminogen activator 
(uPA, PLAU), gene intimately linked to invasion 
mechanisms (Harbeck et al., 2004) as well as of ERβ, 
involved, as highlighted earlier, in breast cancer ll
growth (Han et al., 2005). 
3.4 SRAP expression and relevance to breast cancer 
SRAP expression was assessed by Tissue Microarray 
(TMA) analysis of 372 breast tumors (Yan et al., 2009). 
SRAP levels were significantly higher in estrogen 
receptor-alpha positive, in progesterone receptor 
positive and in older patients (age > 64). When 
considering ER+ tumors, PR+ tumors, or young 
patients (≤ 64 years), patients with high SRAP 
expression had a significantly worse breast cancer 
specific survival (BCSS) than patients with low SRAP 
levels. SRAP also appeared as a very powerful 
indicator of poor prognostic for BCSS in the subset of 
ER+, node negative and young breast cancer patients. 
Altogether suggest that SRAP levels might provide 
additional information on potential risk of recurrenc  
and negative outcome in a specific set of patients. 
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4. Conclusion 
Accumulated data suggest that the bi-faceted 
SRA/SRAP system, including SRA non-coding RNA 
and SRA protein, regulates estrogen receptor signaling 
pathways and plays a critical role in breast 
tumorigenesis and tumor progression. SRA is the first
example of a new kind of molecules active at both 
RNA as well as at the protein levels. Investigating and 
understanding this bi-faceted system might open a new 
era of novel preventive or therapeutic strategies for 
breast cancer patients. 
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